Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 3 , Pages 207-214 , May 2009

Fourteen-year longitudinal study of vascular risk factors, APOE genotype, and cognition: The ARIC MRI Study

  • David S. Knopman

      Affiliations

    • Department of Neurology, Mayo Clinic, Rochester, MN, USA
    • Corresponding Author InformationCorresponding author. Tel.: 507-538-1038; Fax: 507-538-6012.
    • ,
  • Thomas H. Mosley

      Affiliations

    • Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA
    • ,
  • Diane J. Catellier

      Affiliations

    • Department of Biostatistics, University of North Carolina, Chapel Hill, NC, USA
    • ,
  • Laura H. Coker

      Affiliations

    • Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, USA
    • ,
  • Atherosclerosis Risk in Communities Study Brain MRI Study

References 

  1. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, et al. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:49–55
  2. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64:277–281
  3. Carmelli D, Swan GE, Reed T, Miller B, Wolf PA, Jarvik GP, et al. Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins. Neurology. 1998;50:1580–1585
  4. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA. 1995;274:1846–1851
  5. Cerhan JR, Folsom AR, Mortimer JA, Shahar E, Knopman DS, McGovern PG, et al. Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities (ARIC) Study investigators. Gerontology. 1998;44:95–105
  6. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56:42–48
  7. Blair CK, Folsom AR, Knopman DS, Bray MS, Mosley TH, Boerwinkle E, et al. Apolipoprotein E genotype and cognitive decline in a middle-aged cohort. Neurology. 2005;64:268–276
  8. ARIC Investigators . The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol. 1989;129:687–702
  9. Knopman DS, Mosley TH, Catellier DJ, Sharrett AR. Cardiovascular risk factors and cerebral atrophy in a middle-aged cohort. Neurology. 2005;65:876–881
  10. Mosley TH, Knopman DS, Catellier DJ, Bryan N, Hutchinson RG, Grothues CA, et al. Cerebral MRI findings and cognitive functioning: the Atherosclerosis Risk in Communities Study. Neurology. 2005;64:2056–2062
  11. Rosamond WD, Folsom AR, Chambless LE, Wang CH, McGovern PG, Howard G, et al. Stroke incidence and survival among middle-aged adults: 9-year follow- up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke. 1999;30:736–743
  12. Toole JF, Lefkowitz DS, Chambless LE, Wijnberg L, Paton CC, Heiss G. Self-reported transient ischemic attack and stroke symptoms: methods and baseline prevalence. The ARIC Study, 1987–1989. Am J Epidemiol. 1996;144:849–856
  13. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  14. Riley WA, Barnes RW, Applegate WB, Dempsey R, Hartwell T, Davis VG, et al. Reproducibility of noninvasive ultrasonic measurement of carotid atherosclerosis. The Asymptomatic Carotid Artery Plaque Study. Stroke. 1992;23:1062–1068
  15. Knopman DS, Ryberg S. A verbal memory test with high predictive accuracy for dementia of the Alzheimer type. Arch Neurol. 1989;46:141–145
  16. Wechsler D. Wechsler adult intelligence scale-revised. New York: Psychological Corp.; 1981;
  17. Lezak MD. Neuropsychological assessment. 3rd ed.. New York: Oxford University Press; 1995;
  18. Folstein MF, Folstein SE, McHugh PR. Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  19. Andresen EM, Malmgren JA, Carter WB, Patrick DL. Screening for depression in well older adults: evaluation of a short form of the CES-D (Center for Epidemiologic Studies Depression Scale). Am J Prev Med. 1994;10:77–84
  20. Elias MF, Beiser A, Wolf PA, Au R, White RF, D'Agostino RB. The preclinical phase of Alzheimer disease: a 22-year prospective study of the Framingham cohort. Arch Neurol. 2000;57:808–813
  21. Jacobs DM, Sano M, Dooneief G, Marder K, Bell KL, Stern Y. Neuropsychological detection and characterization of preclinical Alzheimer's disease. Neurology. 1995;45:957–962
  22. Howieson DB, Dame A, Camicioli R, Sexton G, Payami H, Kaye JA. Cognitive markers preceding Alzheimer's dementia in the healthy oldest old. J Am Geriatr Soc. 1997;45:584–589
  23. Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, et al. Risk factors for dementia in the Cardiovascular Health Cognition Study. Neuroepidemiology. 2003;22:13–22
  24. Masur DM, Sliwinski M, Lipton RB, Blau AD, Crystal HA. Neuropsychological prediction of dementia and the absence of dementia in healthy elderly persons. Neurology. 1994;44:1427–1432
  25. Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP, Yaffe K. Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. Br Med J [Clin Res]. 2005;330:1360–1364
  26. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56:1683–1689
  27. Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med. 1998;338:506–511
  28. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274–1278
  29. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, et al. Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003;60:246–252
  30. Reed T, Carmelli D, Swan GE, Breitner JC, Welsh KA, Jarvik GP, et al. Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol. 1994;51:1189–1192
  31. Knopman DS, Roberts RO, Geda YE, Boeve BF, Pankratz VS, Cha RH, et al. Association of prior stroke with cognitive function and cognitive impairment: a population-based study. Arch Neurol (in press).
  32. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, Jolles J, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol. 2000;47:145–151
  33. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, et al. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128:2034–2041
  34. Reed BR, Eberling JL, Mungas D, Weiner M, Kramer JH, Jagust WJ. Effects of white matter lesions and lacunes on cortical function. Arch Neurol. 2004;61:1545–1550
  35. Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF, et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol. 2008;65:1066–1073
  36. Haan MN, Shemanski L, Jagust WJ, Manolio TA, Kuller L. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA. 1999;282:40–46
  37. Wilson RS, Schneider JA, Barnes LL, Beckett LA, Aggarwal NT, Cochran EJ, et al. The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. Arch Neurol. 2002;59:1154–1160
  38. Mayeux R, Small SA, Tang M, Tycko B, Stern Y. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging. 2001;22:683–689
  39. Reitz C, Luchsinger JA, Tang MX, Manly J, Mayeux R. Stroke and memory performance in elderly persons without dementia. Arch Neurol. 2006;63:571–576
  40. Yaffe K, Cauley J, Sands L, Browner W. Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Arch Neurol. 1997;54:1110–1114
  41. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:57–62
  42. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51:1256–1262
  43. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298:1300–1311

 Portions of this work were presented in abstract form at the American Academy of Neurology, Boston, MA, May 2, 2007.

 D.S.K. served on a Data Safety Monitoring Board for Sanofi-Aventis Pharmaceuticals, and is an investigator in a clinical trial sponsored by Elan Pharmaceuticals and Forest Pharmaceuticals.

 The Atherosclerosis Risk in Communities Study is performed as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. This work was also supported by grant National Heart, Lung and Blood Institute R01- HL70825.

PII: S1552-5260(09)00030-2

doi: 10.1016/j.jalz.2009.01.027

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 5, Issue 3 , Pages 207-214 , May 2009

Article Tools